Towards rational and evidence-based use of melatonin in prostate cancer prevention and treatment
Article first published online: 19 APR 2007
Journal of Pineal Research
Volume 43, Issue 1, pages 1–9, August 2007
How to Cite
Shiu, S. Y. W. (2007), Towards rational and evidence-based use of melatonin in prostate cancer prevention and treatment. Journal of Pineal Research, 43: 1–9. doi: 10.1111/j.1600-079X.2007.00451.x
- Issue published online: 19 APR 2007
- Article first published online: 19 APR 2007
- Received January 31, 2007; accepted March 15, 2007.
- MT1 receptor;
- prostate cancer;
- prostate-specific antigen
Abstract: Prostate cancer is a public health problem of the elderly men. It has been estimated that one in six men will develop prostate cancer in his lifetime in the USA. There is thus a huge clinical demand for effective therapies for the prevention and treatment of the disease. Here, the scientific evidence supporting the effectiveness of melatonin in inhibiting the development and progression of prostate cancer is reviewed. The rational use of melatonin in prostate cancer prevention, stabilization of clinically localized favourable-risk prostate cancer and palliative treatment of advanced or metastatic tumour is discussed within the context of the molecular pathogenesis of the disease.